Egyptian International Pharmaceutical Investments (CAI:PHAR) EBIT: E£2,469 Mil (TTM As of Mar. 2026)


CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
69 GF Score
Price E£88.50
GF Value E£59.67
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments EBIT?

Egyptian International Pharmaceutical Investments CAI:PHAR +0.02% 69 EBIT is E£2,469 Mil as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 69/100 and a GF Value™ of E£59.67 (Significantly Overvalued). The stock has 12 warning signs investors should review.

Egyptian International Pharmaceutical Investments's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was E£703 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was E£2,469 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Egyptian International Pharmaceutical Investments's annualized ROC % for the quarter that ended in Mar. 2026 was 13.72%. Egyptian International Pharmaceutical Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 23.72%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Egyptian International Pharmaceutical Investments's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.29%.

Egyptian International Pharmaceutical Investments  (CAI:PHAR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Egyptian International Pharmaceutical Investments's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2979.188 * ( 1 - 29.11% )/( (15011.47 + 15766.418)/ 2 )
=2111.9463732/15388.944
=13.72 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17375.921 - 1207.017 - ( 1157.434 - max(0, 6084.777 - 8722.309+1157.434))
=15011.47

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=18431.886 - 2302.653 - ( 362.815 - max(0, 8459.844 - 8947.368+362.815))
=15766.418

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Egyptian International Pharmaceutical Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2811.508/( ( (7959.065 + max(3926.991, 0)) + (8202.834 + max(3620.189, 0)) )/ 2 )
=2811.508/( ( 11886.056 + 11823.023 )/ 2 )
=2811.508/11854.5395
=23.72 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1663.285 + 3789.618 + 166.674) - (1207.017 + 0 + 485.569)
=3926.991

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2379.843 + 4046.838 + 259.042) - (2302.653 + 0 + 762.881)
=3620.189

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Egyptian International Pharmaceutical Investments's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=2469.304/24004.082
=10.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments EBIT Related Terms

Egyptian International Pharmaceutical Investments EBIT Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments EBIT Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 704.87 790.42 1,000.17 1,471.78 2,458.91

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 492.66 759.86 989.31 777.12 702.88

CAI:PHAR vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's EV-to-EBIT falls into.


CAI:PHAR
69GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£2,469 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of E£2,469 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a EBIT of E£2,469 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Egyptian International Pharmaceutical Investments.
Is Egyptian International Pharmaceutical Investments' EBIT too high?
Egyptian International Pharmaceutical Investments' current EBIT is E£2,469 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' EBIT compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' EBIT of E£2,469 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Egyptian International Pharmaceutical Investments. Egyptian International Pharmaceutical Investments's current EBIT is E£2,469 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.67, compared to a current price of E£88.50 — trading 48.3% above its estimated fair value. The current EBIT is E£2,469 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 69/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current EBIT is E£2,469 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£88.50 is trading 48.3% above its estimated GF Value™ of E£59.67. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • EBIT: E£2,469 Mil
  • GF Value™: E£59.67 vs. price of E£88.50 (48.3% above fair value)
  • GF Score™: 69/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
69GF Score

Get the complete analysis for CAI:PHAR

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£88.50
Price
E£59.67
GF Value